Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil

Steven Ira Berk, K. Beckman, T. J. Hoon, R. J. Hariman, D. Hu, F. P. Siegel, J. L. Bauman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Using a dog model, a sublingual form of the free base of verapamil (SLV) was developed with the intent of avoiding stereoselective first-pass metabolism and the necessity of intravenous administration. Intravenous verapamil (IVV) 5 mg and SLV 40 mg or 60 mg were sequentially administered to seven healthy human volunteers. Electrocardiograms and serum concentrations were obtained before and periodically from 5 to 480 minutes after each dose. The time to peak serum concentration (mean ± SD) was 77.6 ± 38.1 minutes after SLV. Bioavailability of SLV was 58.2 ± 36.9% compared to IVV. Verapamil half-lives after IVV and SLV were 2.83 ± 0.93 and 2.28 ± 0.45 hours (NS), respectively. In one subject, the time to peak effect was delayed and overall change in PR interval was minimum. In the remaining six subjects, the maximum percentage increases in PR interval after IVV and SLV were 20.6 ± 6.4% and 14.8 ± 5.5% (p<0.05), respectively. Times to peak increase in PR interval were 28.3 ± 15.7 and 57.0 ± 17.5 minutes after IVV and SLV (p<0.05), respectively. Analysis of plots of percentage change in PR interval versus serum concentration revealed a shift to the right and therefore, lesser effect of SLV than of IVV in six subjects. All seven subjects complained of oral numbness and bitter taste. In conclusion, SLV is inferior to IVV in terms of rate and extent of absorption and pharmacologic effect in delaying atrioventricular nodal conduction. Probably SLV has little clinical utility because of its slow onset and poor tolerance.

Original languageEnglish (US)
Pages (from-to)33-39
Number of pages7
JournalPharmacotherapy
Volume12
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Verapamil
Pharmacokinetics
Serum
Hypesthesia
Intravenous Administration
Biological Availability
Healthy Volunteers
Electrocardiography
Dogs

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Berk, S. I., Beckman, K., Hoon, T. J., Hariman, R. J., Hu, D., Siegel, F. P., & Bauman, J. L. (1992). Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. Pharmacotherapy, 12(1), 33-39.

Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. / Berk, Steven Ira; Beckman, K.; Hoon, T. J.; Hariman, R. J.; Hu, D.; Siegel, F. P.; Bauman, J. L.

In: Pharmacotherapy, Vol. 12, No. 1, 1992, p. 33-39.

Research output: Contribution to journalArticle

Berk, SI, Beckman, K, Hoon, TJ, Hariman, RJ, Hu, D, Siegel, FP & Bauman, JL 1992, 'Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil', Pharmacotherapy, vol. 12, no. 1, pp. 33-39.
Berk, Steven Ira ; Beckman, K. ; Hoon, T. J. ; Hariman, R. J. ; Hu, D. ; Siegel, F. P. ; Bauman, J. L. / Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. In: Pharmacotherapy. 1992 ; Vol. 12, No. 1. pp. 33-39.
@article{28727a56f4604ec8985b23e9bf5b7f8c,
title = "Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil",
abstract = "Using a dog model, a sublingual form of the free base of verapamil (SLV) was developed with the intent of avoiding stereoselective first-pass metabolism and the necessity of intravenous administration. Intravenous verapamil (IVV) 5 mg and SLV 40 mg or 60 mg were sequentially administered to seven healthy human volunteers. Electrocardiograms and serum concentrations were obtained before and periodically from 5 to 480 minutes after each dose. The time to peak serum concentration (mean ± SD) was 77.6 ± 38.1 minutes after SLV. Bioavailability of SLV was 58.2 ± 36.9{\%} compared to IVV. Verapamil half-lives after IVV and SLV were 2.83 ± 0.93 and 2.28 ± 0.45 hours (NS), respectively. In one subject, the time to peak effect was delayed and overall change in PR interval was minimum. In the remaining six subjects, the maximum percentage increases in PR interval after IVV and SLV were 20.6 ± 6.4{\%} and 14.8 ± 5.5{\%} (p<0.05), respectively. Times to peak increase in PR interval were 28.3 ± 15.7 and 57.0 ± 17.5 minutes after IVV and SLV (p<0.05), respectively. Analysis of plots of percentage change in PR interval versus serum concentration revealed a shift to the right and therefore, lesser effect of SLV than of IVV in six subjects. All seven subjects complained of oral numbness and bitter taste. In conclusion, SLV is inferior to IVV in terms of rate and extent of absorption and pharmacologic effect in delaying atrioventricular nodal conduction. Probably SLV has little clinical utility because of its slow onset and poor tolerance.",
author = "Berk, {Steven Ira} and K. Beckman and Hoon, {T. J.} and Hariman, {R. J.} and D. Hu and Siegel, {F. P.} and Bauman, {J. L.}",
year = "1992",
language = "English (US)",
volume = "12",
pages = "33--39",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil

AU - Berk, Steven Ira

AU - Beckman, K.

AU - Hoon, T. J.

AU - Hariman, R. J.

AU - Hu, D.

AU - Siegel, F. P.

AU - Bauman, J. L.

PY - 1992

Y1 - 1992

N2 - Using a dog model, a sublingual form of the free base of verapamil (SLV) was developed with the intent of avoiding stereoselective first-pass metabolism and the necessity of intravenous administration. Intravenous verapamil (IVV) 5 mg and SLV 40 mg or 60 mg were sequentially administered to seven healthy human volunteers. Electrocardiograms and serum concentrations were obtained before and periodically from 5 to 480 minutes after each dose. The time to peak serum concentration (mean ± SD) was 77.6 ± 38.1 minutes after SLV. Bioavailability of SLV was 58.2 ± 36.9% compared to IVV. Verapamil half-lives after IVV and SLV were 2.83 ± 0.93 and 2.28 ± 0.45 hours (NS), respectively. In one subject, the time to peak effect was delayed and overall change in PR interval was minimum. In the remaining six subjects, the maximum percentage increases in PR interval after IVV and SLV were 20.6 ± 6.4% and 14.8 ± 5.5% (p<0.05), respectively. Times to peak increase in PR interval were 28.3 ± 15.7 and 57.0 ± 17.5 minutes after IVV and SLV (p<0.05), respectively. Analysis of plots of percentage change in PR interval versus serum concentration revealed a shift to the right and therefore, lesser effect of SLV than of IVV in six subjects. All seven subjects complained of oral numbness and bitter taste. In conclusion, SLV is inferior to IVV in terms of rate and extent of absorption and pharmacologic effect in delaying atrioventricular nodal conduction. Probably SLV has little clinical utility because of its slow onset and poor tolerance.

AB - Using a dog model, a sublingual form of the free base of verapamil (SLV) was developed with the intent of avoiding stereoselective first-pass metabolism and the necessity of intravenous administration. Intravenous verapamil (IVV) 5 mg and SLV 40 mg or 60 mg were sequentially administered to seven healthy human volunteers. Electrocardiograms and serum concentrations were obtained before and periodically from 5 to 480 minutes after each dose. The time to peak serum concentration (mean ± SD) was 77.6 ± 38.1 minutes after SLV. Bioavailability of SLV was 58.2 ± 36.9% compared to IVV. Verapamil half-lives after IVV and SLV were 2.83 ± 0.93 and 2.28 ± 0.45 hours (NS), respectively. In one subject, the time to peak effect was delayed and overall change in PR interval was minimum. In the remaining six subjects, the maximum percentage increases in PR interval after IVV and SLV were 20.6 ± 6.4% and 14.8 ± 5.5% (p<0.05), respectively. Times to peak increase in PR interval were 28.3 ± 15.7 and 57.0 ± 17.5 minutes after IVV and SLV (p<0.05), respectively. Analysis of plots of percentage change in PR interval versus serum concentration revealed a shift to the right and therefore, lesser effect of SLV than of IVV in six subjects. All seven subjects complained of oral numbness and bitter taste. In conclusion, SLV is inferior to IVV in terms of rate and extent of absorption and pharmacologic effect in delaying atrioventricular nodal conduction. Probably SLV has little clinical utility because of its slow onset and poor tolerance.

UR - http://www.scopus.com/inward/record.url?scp=0026530187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026530187&partnerID=8YFLogxK

M3 - Article

C2 - 1549537

AN - SCOPUS:0026530187

VL - 12

SP - 33

EP - 39

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1

ER -